GFAP expression is influenced by astrocytoma grade and rs2070935 polymorphism

Mantas Sereika,Ruta Urbanaviciute,Arimantas Tamasauskas,Daina Skiriute,Paulina Vaitkiene
DOI: https://doi.org/10.7150/jca.26769
IF: 3.9
2018-01-01
Journal of Cancer
Abstract:Glial fibrillary acidic protein (GFAP) is an intermediate filament that provides mechanical support to astrocytes. <i>Rs2070935</i> is a single nucleotide polymorphism (SNP) located in the promoter region of the <i>GFAP</i> gene. The aim of this pilot study is to investigate <i>GFAP</i> expression at mRNA, protein levels and <i>rs2070935</i> polymorphism in 50 different grade human astrocytoma samples. <i>GFAP</i> expression at mRNA level was measured using quantitative reverse transcription polymerase chain reaction (qRT-PCR) with SYBR Green dye, whereas the translational activity of the following gene was detected using western blot assay. Furthermore, genotypes of <i>rs2070935</i> were identified using qPCR with TaqMan probes. As a result, <i>GFAP</i> mRNA and protein expression was found to be declining with increasing astrocytoma grade (p &lt; 0.05). A tendency was observed between increased <i>GFAP</i> mRNA expression and shorter grade IV astrocytoma patient survival (p = 0.2117). The <i>rs2070935</i> CC genotype was found to be associated with increased <i>GFAP</i> translational activity in grade II astrocytoma (p = 0.0238). Possible links between <i>rs2070935</i> genotypes and alternative splicing of <i>GFAP</i> were also observed. The <i>rs2070935</i> AA genotype was found to be associated with poor clinical outcome for grade IV astrocytoma patients (p = 0.0007), although the following data should be checked in a larger sample size of astrocytoma patients.
oncology
What problem does this paper attempt to address?